Do BPC-157 capsules work?

No human study has tested them. Rodent work did administer BPC-157 orally and reported effects, which is unusual for a peptide, but no oral bioavailability figure has ever been published in any species.

Is oral BPC-157 destroyed by stomach acid?

The argument that it survives comes from its origin in a gastric juice protein, which is a reasonable prior rather than a measurement. What is established is that oral dosing produced effects in rats, not how much intact peptide was absorbed.

Are capsules better than injection?

Nothing supports a comparison. Both routes were used in rodent studies and neither has a measured bioavailability figure or any human data.

BPC-157 (Pentadecapeptide)

Is Oral BPC-157 Absorbed? What the Rat Data Shows

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-313 cited sources

BPC-157 is unusual among peptides: the original rodent studies administered it orally as well as by injection, and reported effects either way. That is a genuine finding and it is not the same as a measured oral bioavailability, which has never been published — in rats or in people.

Key facts

Oral rodent dosing: Used in the original work
Measured oral bioavailability: Never published
Human data of any kind: None
Claimed stability basis: Gastric juice origin
What a capsule contains: Unverifiable without a CoA

Why this question has a different answer to most peptides

The usual response is that peptides are destroyed by digestion, and for most of them that is correct. BPC-157 is the exception people cite, and the citation is real: the Zagreb group's rodent work administered it in drinking water and intragastrically, not only by injection, and reported effects from both routes. That is why the oral question keeps coming up for this compound and not for others.

What that finding does not establish

Reporting an effect after oral administration is not the same as measuring how much intact peptide reached circulation. No pharmacokinetic study has published an oral bioavailability figure for BPC-157 in any species. The effect could follow from a small absorbed fraction, from local action in the gut itself, or from a metabolite. The experiments were not designed to distinguish those.

Research material referenced

BPC-157 5mg — third-party HPLC tested

View — £15.99

The gastric-juice argument, in proportion

The stability claim is usually argued from origin: BPC-157 derives from a sequence found in gastric juice, so it is presented as inherently resistant to that environment. It is a reasonable prior and it is not a measurement. Being found in a compartment is not proof of surviving it intact at a useful concentration.

And nothing here is about a human capsule

Every finding above comes from rats. No human study of oral BPC-157 has been published, no dose has been established, and no regulator has assessed a product containing it — the FDA placed the compound in Category 2 of its 503A bulk substances review in 2023. A capsule sold on the strength of rodent drinking-water experiments is extrapolating a long way.

Quick reference

	Injected	Oral
Used in rodent studies	Yes	Yes
Effects reported	Yes	Yes
Bioavailability measured	No	No
Human data	None	None

Extended research context

The BPC-157 (Pentadecapeptide) deep dive

Deep dive: the pentadecapeptide sequence

BPC-157 is a synthetic pentadecapeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is derived from a fragment identified in human gastric juice by the Zagreb research group (Sikirić and colleagues), whose body of published work spans three decades and covers models ranging from tendon repair to gut integrity. The 'BPC' initials stand for 'body protection compound' — the group's original characterisation term.

Two forms: acetate salt vs arginate

BPC-157 is supplied most commonly as an acetate salt; a small subset of suppliers offer the arginate form, which has slightly different solubility and stability properties. For research reproducibility, keep the salt form consistent across a study and confirm which form the CoA specifies (mass ± counterion changes the reading).

Reading a BPC-157 CoA

A trustworthy BPC-157 CoA lists HPLC purity (target ≥98% area), mass-spec confirmation (~1,419 Da for the free peptide), water content (Karl Fischer), acetate content, and residual solvents. Some batches also include endotoxin data. Any missing category is a red flag for a compromised supply chain.

Research applications

▸Cell-culture models of gut epithelial integrity
▸Tendon fibroblast migration and collagen-synthesis assays
▸Angiogenesis models involving VEGF and NO signalling
▸Stability studies comparing acetate vs arginate salt forms
▸Analytical reference for pentadecapeptide HPLC methods

Handling checklist

✓Store lyophilised vial at −20 °C long-term (2–8 °C short-term)
✓Reconstitute with bacteriostatic water; a 5 mg vial dissolves cleanly
✓Aliquot reconstituted solution; keep refrigerated 2–8 °C, use within 28 days
✓Protect from light and repeated warming
✓Verify CoA: HPLC ≥98%, mass ~1,419 Da, salt form declared

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Mixing acetate and arginate BPC-157 across a study

Fix: Choose one salt form and stay with it — different masses and solubility.

✗ Assuming stability at room temperature

Fix: Refrigerate reconstituted solution; discard after 28 days.

✗ Buying without a CoA

Fix: Only source from suppliers that publish batch HPLC + mass-spec data.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Do BPC-157 capsules work?: No human study has tested them. Rodent work did administer BPC-157 orally and reported effects, which is unusual for a peptide, but no oral bioavailability figure has ever been published in any species.
Is oral BPC-157 destroyed by stomach acid?: The argument that it survives comes from its origin in a gastric juice protein, which is a reasonable prior rather than a measurement. What is established is that oral dosing produced effects in rats, not how much intact peptide was absorbed.
Are capsules better than injection?: Nothing supports a comparison. Both routes were used in rodent studies and neither has a measured bioavailability figure or any human data.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More BPC-157 (Pentadecapeptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum